adplus-dvertising
Connect with us

News

'Our plan is working,' Trudeau says amid new vaccine delays – CBC.ca

Published

 on


Prime Minister Justin Trudeau said Friday that he understands why there is a “tremendous amount of anxiety” among Canadians with the constant flow of bad news about the inoculation campaign, but he doubled down on his promise to deliver six million shots by the end of March.

Trudeau asked Canadians to tune out the “noise” from some circles about the sorry state of the country’s vaccine efforts, saying the temporary “ups and downs” may be frustrating to “some people,” but they’re just that — temporary.

Speaking to reporters outside Rideau Cottage, Trudeau said he has been in regular contact with executives at three of the pharmaceutical companies that are supplying Canada with shots.

The two principal suppliers, Moderna and Pfizer, have assured him that they will still meet their contractual obligations to send six million shots, combined, despite dramatic declines in shipments over the last month, Trudeau said.

“I want to reassure Canadians that we’re on track,” he said, adding that as many as 20 million more doses will start to arrive in the spring as the federal government keeps its sights on vaccinating all people who want a shot by the end of September.

WATCH: Trudeau tells Canadians COVID-19 vaccine target is still on track:

Prime Minister Justin Trudeau made the remarks during his opening address to Canadians about the state of the fight against the virus on Friday. 3:02

Asked if Canada had any legal recourse if the companies don’t meet their contractual obligations, Trudeau didn’t answer. Treasury Board President Jean-Yves Duclos also declined to comment Friday on the government’s legal options if the companies fail to meet delivery targets for the first quarter of this year.

The two companies are grappling with manufacturing issues at their plants in Europe that have severely disrupted deliveries to markets outside the U.S.

While Canada’s Moderna supply will be curtailed this month — public health officials have conceded that they have no idea just how much product will arrive.

Meanwhile shipments in the U.S. have increased by about 35 per cent in the last week as Moderna looks to fulfil its obligations to a government that partially funded vaccine development.

AstraZeneca awaits green light

Trudeau said the pending approval of other promising vaccine candidates will be a much-needed jolt to the stalled vaccination campaign — Canada now ranks 33rd worldwide for shots administered per capita — and he spoke with the CEO of AstraZeneca this week, who told him vaccines would follow shortly after Health Canada’s green light.

Canada passed on the domestic manufacturing rights to that product, so the shipments will come from the company’s factories abroad. Canada has ordered up to 20 million doses of that product, which is already in use in Europe and the United Kingdom.

Trudeau suggested those AstraZeneca shots would be delivered sometime this summer — “He very much assured me that we are on track to receiving the 20 million doses committed to by the end of June,” Trudeau said of the CEO, Pascal Soriot.

But a procurement official, speaking on background, later clarified that the entirety of the AstraZeneca order would not arrive until the end of the third quarter, in September.

Public Services and Procurement Minister Anita Anand told the Commons health committee Friday that some 500,000 AstraZeneca shots could arrive before the end of March now that Canada has chosen to tap supply from COVAX, a vaccine-sharing initiative funded by wealthier countries to ensure low- and middle-income countries have access to shots.

WATCH: Trudeau discusses the AstraZeneca COVID-19 vaccine:

Dr. Theresa Tam responds to questions about at what point will Canada’s vaccination rate lead to lifting stay-at-home orders. 2:28

Amid production delays at plants in Europe, some observers, notably Ontario Premier Doug Ford, have suggested Canada should turn to the U.S. for a lifeline because manufacturing continues there unaffected.

Pfizer has a plant in Kalamazoo, Mich., which is only 220 kilometres from the Detroit-Windsor crossing, and Moderna is manufacturing vials in Massachusetts and New Hampshire.

Anand said she recently spoke with Jeff Zients, a counsellor to U.S. President Joe Biden and the administration’s COVID-19 coordinator, and she was told all production from U.S. factories has been earmarked for Americans, at least for now.

“We continue to follow up with them to see if it’s a possibility for Canada, we’re still having this conversation. I wouldn’t classify it as ‘being turned down,'” Anand told MPs. “All doses, at the current time, are staying in the U.S.”

More than 1.2 million Moderna and Pfizer shots have already been delivered in Canada, with an estimated 1.3 million more shots slated to arrive this month.

That means more than 3.5 million shots have to be delivered in the month of March alone — some 885,000 a week — to meet the prime minister’s promised vaccination target, a daunting task for the country’s public health system. Trudeau said the country is preparing for the onslaught of hundreds of thousands of shots.

“Our plan is working,” Trudeau said in French. “Temporary shipment delays are a hurdle but one that we were ready for.”

WATCH: Dr. Tam is asked about vaccination rates and lifting lockdowns

Prime Minister Justin Trudeau spoke with reporters about the Health Canada approval process for the AstraZeneca vaccine. 0:52

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

News

STD epidemic slows as new syphilis and gonorrhea cases fall in US

Published

 on

 

NEW YORK (AP) — The U.S. syphilis epidemic slowed dramatically last year, gonorrhea cases fell and chlamydia cases remained below prepandemic levels, according to federal data released Tuesday.

The numbers represented some good news about sexually transmitted diseases, which experienced some alarming increases in past years due to declining condom use, inadequate sex education, and reduced testing and treatment when the COVID-19 pandemic hit.

Last year, cases of the most infectious stages of syphilis fell 10% from the year before — the first substantial decline in more than two decades. Gonorrhea cases dropped 7%, marking a second straight year of decline and bringing the number below what it was in 2019.

“I’m encouraged, and it’s been a long time since I felt that way” about the nation’s epidemic of sexually transmitted infections, said the CDC’s Dr. Jonathan Mermin. “Something is working.”

More than 2.4 million cases of syphilis, gonorrhea and chlamydia were diagnosed and reported last year — 1.6 million cases of chlamydia, 600,000 of gonorrhea, and more than 209,000 of syphilis.

Syphilis is a particular concern. For centuries, it was a common but feared infection that could deform the body and end in death. New cases plummeted in the U.S. starting in the 1940s when infection-fighting antibiotics became widely available, and they trended down for a half century after that. By 2002, however, cases began rising again, with men who have sex with other men being disproportionately affected.

The new report found cases of syphilis in their early, most infectious stages dropped 13% among gay and bisexual men. It was the first such drop since the agency began reporting data for that group in the mid-2000s.

However, there was a 12% increase in the rate of cases of unknown- or later-stage syphilis — a reflection of people infected years ago.

Cases of syphilis in newborns, passed on from infected mothers, also rose. There were nearly 4,000 cases, including 279 stillbirths and infant deaths.

“This means pregnant women are not being tested often enough,” said Dr. Jeffrey Klausner, a professor of medicine at the University of Southern California.

What caused some of the STD trends to improve? Several experts say one contributor is the growing use of an antibiotic as a “morning-after pill.” Studies have shown that taking doxycycline within 72 hours of unprotected sex cuts the risk of developing syphilis, gonorrhea and chlamydia.

In June, the CDC started recommending doxycycline as a morning-after pill, specifically for gay and bisexual men and transgender women who recently had an STD diagnosis. But health departments and organizations in some cities had been giving the pills to people for a couple years.

Some experts believe that the 2022 mpox outbreak — which mainly hit gay and bisexual men — may have had a lingering effect on sexual behavior in 2023, or at least on people’s willingness to get tested when strange sores appeared.

Another factor may have been an increase in the number of health workers testing people for infections, doing contact tracing and connecting people to treatment. Congress gave $1.2 billion to expand the workforce over five years, including $600 million to states, cities and territories that get STD prevention funding from CDC.

Last year had the “most activity with that funding throughout the U.S.,” said David Harvey, executive director of the National Coalition of STD Directors.

However, Congress ended the funds early as a part of last year’s debt ceiling deal, cutting off $400 million. Some people already have lost their jobs, said a spokeswoman for Harvey’s organization.

Still, Harvey said he had reasons for optimism, including the growing use of doxycycline and a push for at-home STD test kits.

Also, there are reasons to think the next presidential administration could get behind STD prevention. In 2019, then-President Donald Trump announced a campaign to “eliminate” the U.S. HIV epidemic by 2030. (Federal health officials later clarified that the actual goal was a huge reduction in new infections — fewer than 3,000 a year.)

There were nearly 32,000 new HIV infections in 2022, the CDC estimates. But a boost in public health funding for HIV could also also help bring down other sexually transmitted infections, experts said.

“When the government puts in resources, puts in money, we see declines in STDs,” Klausner said.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Source link

Continue Reading

News

World’s largest active volcano Mauna Loa showed telltale warning signs before erupting in 2022

Published

 on

 

WASHINGTON (AP) — Scientists can’t know precisely when a volcano is about to erupt, but they can sometimes pick up telltale signs.

That happened two years ago with the world’s largest active volcano. About two months before Mauna Loa spewed rivers of glowing orange molten lava, geologists detected small earthquakes nearby and other signs, and they warned residents on Hawaii‘s Big Island.

Now a study of the volcano’s lava confirms their timeline for when the molten rock below was on the move.

“Volcanoes are tricky because we don’t get to watch directly what’s happening inside – we have to look for other signs,” said Erik Klemetti Gonzalez, a volcano expert at Denison University, who was not involved in the study.

Upswelling ground and increased earthquake activity near the volcano resulted from magma rising from lower levels of Earth’s crust to fill chambers beneath the volcano, said Kendra Lynn, a research geologist at the Hawaiian Volcano Observatory and co-author of a new study in Nature Communications.

When pressure was high enough, the magma broke through brittle surface rock and became lava – and the eruption began in late November 2022. Later, researchers collected samples of volcanic rock for analysis.

The chemical makeup of certain crystals within the lava indicated that around 70 days before the eruption, large quantities of molten rock had moved from around 1.9 miles (3 kilometers) to 3 miles (5 kilometers) under the summit to a mile (2 kilometers) or less beneath, the study found. This matched the timeline the geologists had observed with other signs.

The last time Mauna Loa erupted was in 1984. Most of the U.S. volcanoes that scientists consider to be active are found in Hawaii, Alaska and the West Coast.

Worldwide, around 585 volcanoes are considered active.

Scientists can’t predict eruptions, but they can make a “forecast,” said Ben Andrews, who heads the global volcano program at the Smithsonian Institution and who was not involved in the study.

Andrews compared volcano forecasts to weather forecasts – informed “probabilities” that an event will occur. And better data about the past behavior of specific volcanos can help researchers finetune forecasts of future activity, experts say.

(asterisk)We can look for similar patterns in the future and expect that there’s a higher probability of conditions for an eruption happening,” said Klemetti Gonzalez.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

News

Waymo’s robotaxis now open to anyone who wants a driverless ride in Los Angeles

Published

 on

 

Waymo on Tuesday opened its robotaxi service to anyone who wants a ride around Los Angeles, marking another milestone in the evolution of self-driving car technology since the company began as a secret project at Google 15 years ago.

The expansion comes eight months after Waymo began offering rides in Los Angeles to a limited group of passengers chosen from a waiting list that had ballooned to more than 300,000 people. Now, anyone with the Waymo One smartphone app will be able to request a ride around an 80-square-mile (129-square-kilometer) territory spanning the second largest U.S. city.

After Waymo received approval from California regulators to charge for rides 15 months ago, the company initially chose to launch its operations in San Francisco before offering a limited service in Los Angeles.

Before deciding to compete against conventional ride-hailing pioneers Uber and Lyft in California, Waymo unleashed its robotaxis in Phoenix in 2020 and has been steadily extending the reach of its service in that Arizona city ever since.

Driverless rides are proving to be more than just a novelty. Waymo says it now transports more than 50,000 weekly passengers in its robotaxis, a volume of business numbers that helped the company recently raise $5.6 billion from its corporate parent Alphabet and a list of other investors that included venture capital firm Andreesen Horowitz and financial management firm T. Rowe Price.

“Our service has matured quickly and our riders are embracing the many benefits of fully autonomous driving,” Waymo co-CEO Tekedra Mawakana said in a blog post.

Despite its inroads, Waymo is still believed to be losing money. Although Alphabet doesn’t disclose Waymo’s financial results, the robotaxi is a major part of an “Other Bets” division that had suffered an operating loss of $3.3 billion through the first nine months of this year, down from a setback of $4.2 billion at the same time last year.

But Waymo has come a long way since Google began working on self-driving cars in 2009 as part of project “Chauffeur.” Since its 2016 spinoff from Google, Waymo has established itself as the clear leader in a robotaxi industry that’s getting more congested.

Electric auto pioneer Tesla is aiming to launch a rival “Cybercab” service by 2026, although its CEO Elon Musk said he hopes the company can get the required regulatory clearances to operate in Texas and California by next year.

Tesla’s projected timeline for competing against Waymo has been met with skepticism because Musk has made unfulfilled promises about the company’s self-driving car technology for nearly a decade.

Meanwhile, Waymo’s robotaxis have driven more than 20 million fully autonomous miles and provided more than 2 million rides to passengers without encountering a serious accident that resulted in its operations being sidelined.

That safety record is a stark contrast to one of its early rivals, Cruise, a robotaxi service owned by General Motors. Cruise’s California license was suspended last year after one of its driverless cars in San Francisco dragged a jaywalking pedestrian who had been struck by a different car driven by a human.

Cruise is now trying to rebound by joining forces with Uber to make some of its services available next year in U.S. cities that still haven’t been announced. But Waymo also has forged a similar alliance with Uber to dispatch its robotaxi in Atlanta and Austin, Texas next year.

Another robotaxi service, Amazon’s Zoox, is hoping to begin offering driverless rides to the general public in Las Vegas at some point next year before also launching in San Francisco.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending